The shares of NovoCure Limited (NASDAQ: NVCR) jumped 39.67% to $27.99 as of the last check during current session. The encouraging findings of the Phase 3 PANOVA-3 clinical investigation were followed by that spike in NVCR shares on US stock charts.
NovoCure Is Advancing in Pancreatic Cancer Therapy
The PANOVA-3 research looked at how well Tumor Treating Fields (TTFields) therapy worked for patients with locally advanced, incurable pancreatic adenocarcinoma when combined with gemcitabine and nab-paclitaxel. With a statistically significant increase in median overall survival (mOS), the Phase 3 study’s main objective was accomplished. Patients receiving the TTFields combination therapy reported a mOS of 16.20 months compared to 14.16 months in those treated with gemcitabine and nab-paclitaxel alone.
Potential Advantages for Survival
The study demonstrated that patients treated with TTFields had a greater survival benefit over time. The survival rate increased 13% after 12 months and an astounding 33% after 24 months. With safety results in line with earlier clinical research, these findings demonstrate that TTFields treatment is a viable and well-tolerated alternative.
The trial’s secondary objectives, in addition to mOS, were toxicity, quality of life, and progression-free survival. Further solidifying NovoCure’s oncology breakthroughs, PANOVA-3 is the first Phase 3 study to demonstrate a notable survival advantage for unresectable, locally advanced pancreatic cancer.
Prospects for the Future and Further Research
NovoCure intends to request regulatory clearance for TTFields treatment in pancreatic cancer in light of these findings. In order to include the larger scientific community, the findings will also be presented at a future medical convention.
As part of its ongoing Phase 2 PANOVA-4 study, NovoCure is investigating TTFields treatment in combination with atezolizumab, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer, demonstrating that its innovation goes beyond PANOVA-3. Data from PANOVA-4 is anticipated by 2026 once recruitment is complete, providing optimism for more progress in this difficult area.
These advancements further NovoCure’s dedication to developing novel treatments for tumors that are difficult to cure.
